As of Feb 24
| 0.00 / 0.00%|
The 1 analysts offering 12-month price forecasts for InVivo Therapeutics Holdings Corp have a median target of 23.25, with a high estimate of 23.25 and a low estimate of 23.25. The median estimate represents a +440.70% increase from the last price of 4.30.
The current consensus among 2 polled investment analysts is to Buy stock in InVivo Therapeutics Holdings Corp. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.